{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.92","value":"2.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Hardness will be measured by Ramen nano-indentation and mineralization measured by histomorphometry obtained (in GPa).","dispersionType":"Standard Error","groups":[{"description":"Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.\n\nEtelcalcetide: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.","id":"OG000","title":"Study Participant"}],"paramType":"MEAN","populationDescription":"Only includes participants who completed the histomorphometry.","reportingStatus":"POSTED","timeFrame":"Baseline and 9 months","title":"Percent Change in Mean Hardness","type":"PRIMARY","unitOfMeasure":"percent of change in hardness"}